Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.5 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.76 | |||||
| Beneish M-Score | -4.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -81.7 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -20.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.12 | |||||
| 9-Day RSI | 39.12 | |||||
| 14-Day RSI | 42.06 | |||||
| 6-1 Month Momentum % | 59.17 | |||||
| 12-1 Month Momentum % | 24.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.27 | |||||
| Quick Ratio | 6.27 | |||||
| Cash Ratio | 5.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -79.1 | |||||
| Shareholder Yield % | -68.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -15557.79 | |||||
| Net Margin % | -14274.5 | |||||
| FCF Margin % | -10468.28 | |||||
| ROE % | -52.86 | |||||
| ROA % | -41.23 | |||||
| ROIC % | -297.71 | |||||
| ROC (Joel Greenblatt) % | -399.52 | |||||
| ROCE % | -50.67 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 270 | |||||
| PB Ratio | 1.13 | |||||
| Price-to-Tangible-Book | 1.13 | |||||
| EV-to-EBIT | -0.49 | |||||
| EV-to-Forward-EBIT | -0.38 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Forward-EBITDA | -0.38 | |||||
| EV-to-Revenue | 76.47 | |||||
| EV-to-Forward-Revenue | 5.14 | |||||
| EV-to-FCF | -0.72 | |||||
| Price-to-Net-Current-Asset-Value | 1.41 | |||||
| Price-to-Net-Cash | 1.51 | |||||
| Earnings Yield (Greenblatt) % | -204.08 | |||||
| FCF Yield % | -34.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
aTyr Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.331 | ||
| EPS (TTM) (€) | -0.89 | ||
| Beta | 0.6 | ||
| Volatility % | 47.46 | ||
| 14-Day RSI | 42.06 | ||
| 14-Day ATR (€) | 0.059468 | ||
| 20-Day SMA (€) | 1.624 | ||
| 12-1 Month Momentum % | 24.03 | ||
| 52-Week Range (€) | 0.985 - 2.38 | ||
| Shares Outstanding (Mil) | 67.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
aTyr Pharma Inc Frequently Asked Questions
What is aTyr Pharma Inc(FRA:471A)'s stock price today?
The current price of FRA:471A is €1.50. The 52 week high of FRA:471A is €2.38 and 52 week low is €0.99.
When is next earnings date of aTyr Pharma Inc(FRA:471A)?
The next earnings date of aTyr Pharma Inc(FRA:471A) is 2024-05-09 Est..
Does aTyr Pharma Inc(FRA:471A) pay dividends? If so, how much?
aTyr Pharma Inc(FRA:471A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers